How Does GLP-2 Work? Mechanism of Action, Per the Research

The short answer, as the literature frames it

Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid peptide cut from the same precursor protein as GLP-1, and reviews of proglucagon-derived peptide biology described it as an intestinotrophic hormone released from enteroendocrine L cells of the distal small intestine and colon (PMID 34093449). A comprehensive review of proglucagon-derived peptides in human physiology reported that GLP-2 signals through a single identified receptor, the GLP-2 receptor (GLP-2R), and that the distribution of that receptor is far narrower than the range of tissue responses attributed to the hormone (PMID 40720286). That mismatch is the central feature of the mechanism: an older review of GLP-2 pharmacology described most of its intestinal actions as indirect, relayed from receptor-bearing cells to neighbouring epithelium through local mediators (PMID 16602931).

Step 1: Where the peptide comes from

The proglucagon gene is expressed in pancreatic alpha cells, intestinal L cells and some brainstem neurons, and tissue-specific processing by prohormone convertases determines which peptides are produced; reviews of proglucagon-derived peptides as therapeutics reported that intestinal processing yields GLP-1, GLP-2, glicentin and oxyntomodulin (PMID 34093449). Because GLP-1 and GLP-2 originate from the same precursor in the same cells, reviews described them as being co-secreted in response to luminal nutrients, which is one reason the two peptides are often studied together even though their receptors and dominant actions differ (PMID 16602931). A separate review focused on GLP-1 in intestinal disease reported that the L-cell axis sits at the interface of nutrient sensing, mucosal biology and the gut microbial environment (PMID 33916501).

Degradation by DPP-4

A clinical endocrinology review of GLP-2 reported that the circulating peptide is inactivated by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal dipeptide to generate GLP-2(3-33) and gives the native hormone a short plasma survival (PMID 11297614). Reviews noted that this enzymatic step is the pharmacological reason DPP-4-resistant analogues were developed, since substitution at the cleavage site extends exposure without changing the receptor target (PMID 16602931). The same DPP-4 biology links GLP-2 to the broader incretin field, where reviews of incretins and lipid metabolism discussed shared enzymatic regulation across proglucagon-derived peptides (PMID 28413961).

Step 2: The receptor target

Reviews of GLP-2 pharmacology described GLP-2R as a class B (secretin-family) G-protein-coupled receptor whose activation is classically linked to cyclic AMP generation in receptor-expressing cells (PMID 16602931). The reported expression pattern is restricted rather than ubiquitous: reviews of proglucagon-derived peptide physiology described GLP-2R localisation to enteric neurons, subepithelial myofibroblasts and subsets of enteroendocrine cells, with additional reports in extraintestinal sites (PMID 40720286). Crucially, a review of GLP-2 biology reported that the crypt stem and progenitor cells that actually divide in response to GLP-2 are not the principal cells carrying the receptor, which is why the mechanism is usually drawn as a two-step relay (PMID 16602931).

Step 3: Indirect mediators, the relay step

Reviews of GLP-2 pharmacology reported that receptor activation on neurons and myofibroblasts triggers release of local growth factors and neurotransmitters that then act on the epithelium, with insulin-like growth factor-1 (IGF-1), keratinocyte growth factor and ErbB-family ligands among the mediators repeatedly identified in experimental work (PMID 16602931). Vasoactive intestinal peptide and nitric oxide have been described as mediators of the vascular and neural arm of the response, and a review of proglucagon-derived peptides in human physiology reported that these pathways link GLP-2R activation to changes in mucosal perfusion (PMID 40720286). Much of the mediator-level evidence comes from rodent models and isolated tissue preparations rather than from humans, and reviews labelled it as such (PMID 16602931).

Step 4: Downstream physiology reported in the literature

Mucosal growth

The earliest defining observation was intestinotrophic: a clinical review reported that GLP-2 administration in animal models increased crypt cell proliferation and reduced enterocyte apoptosis, producing greater villus height and mucosal mass (PMID 11297614). A later review reported that this trophic action is the defining pharmacology of the peptide and the basis for interest in intestinal failure (PMID 16602931).

Barrier function and mucosal defence

A review of gastrointestinal defence mechanisms reported that GLP-2 is among the mediators implicated in mucosal protection, including effects on epithelial barrier integrity and mucosal blood flow (PMID 27653163). Reviews of proglucagon-derived peptides also reported reductions in intestinal permeability as a recurring experimental finding attributed to GLP-2R signalling (PMID 40720286).

Nutrient transport and lipid handling

A 2024 review dedicated to GLP-2 regulation of intestinal lipid handling reported that GLP-2 influences the absorption and packaging of dietary lipid by the enterocyte, including chylomicron-related processing, and described this as an active area of mechanistic study (PMID 38426205). A broader review of incretins and lipid metabolism reported that proglucagon-derived peptides sit upstream of postprandial lipid flux through both intestinal and systemic routes (PMID 28413961).

Motility, gastric secretion and transit

A clinical endocrinology review reported that GLP-2 has been associated with slowed gastric emptying and reduced gastric acid secretion in human and animal studies, effects described as part of the "ileal brake" family of responses (PMID 11297614). Reviews of GLP-2 biology reported that longer transit time would plausibly increase contact between nutrients and absorptive surface, although they framed the relative contribution of transit versus mucosal growth as unsettled (PMID 16602931).

Signalling beyond the gut

A review of the gut-bone axis reported that GLP-2 is one of the enteroendocrine signals studied in relation to bone turnover, with investigators examining whether postprandial gut hormone release contributes to the diurnal pattern of bone resorption markers (PMID 36441432). That review treated the gut-bone link as an evolving hypothesis rather than a settled mechanism (PMID 36441432).

Established mechanism versus proposed mechanism

How the mechanism translated into an approved drug class

Reviews of pharmacotherapy for short bowel syndrome reported that a DPP-4-resistant GLP-2 analogue, teduglutide, became the clinical embodiment of this mechanism and is used in intestinal failure with a goal of improving intestinal absorptive capacity (PMID 32057270). A review of enterohormone therapy for short bowel syndrome reported that the therapeutic rationale rests directly on the trophic and absorptive pharmacology described above, and that longer-acting GLP-2 analogues have been investigated to extend receptor exposure (PMID 35034035). Research-grade GLP-2 peptides supplied for laboratory work are a separate category from approved pharmaceuticals and are labelled for research use only; that labelling is a regulatory classification, not a statement about the underlying pharmacology (PMID 34093449).

GLP-2 Pathway Safety Signals: What Studies Report

Because the defining mechanism is growth-promoting, reviews of enterohormone therapy reported that clinical use is accompanied by structured monitoring rather than being treated as consequence-free, and discussed safety considerations alongside efficacy in intestinal failure populations (PMID 35034035). A review of short bowel syndrome pharmacotherapy reported that patient selection, response assessment and ongoing follow-up were central to how the drug class is deployed in practice (PMID 32057270). Reviews of GLP-2 biology noted that the same proliferative signalling that drives mucosal adaptation is the reason researchers have examined growth-related safety questions at the mechanistic level (PMID 16602931). This page does not list product-specific adverse-event rates, because the verified literature summarised here is mechanistic and review-level rather than drawn from individual trial safety tables (PMID 32057270).

What is still unresolved

• Human receptor mapping. A review of proglucagon-derived peptides reported that the precise human cellular distribution of GLP-2R, particularly outside the intestine, remains incompletely defined (PMID 40720286).
• Relative weight of each mediator. Reviews reported that IGF-1 and related growth factors are necessary in several rodent models, but ranking the mediators in humans has not been settled (PMID 16602931).
• Lipid pathway direction. A 2024 review reported that GLP-2's effects on intestinal lipid handling are still being characterised and are not reducible to a single directional statement (PMID 38426205).
• Extraintestinal endpoints. A gut-bone axis review reported that enteroendocrine contributions to skeletal metabolism remain an open research question (PMID 36441432).
• Crosstalk with GLP-1. A review of GLP-1 in intestinal disease reported overlapping L-cell biology, which complicates attributing any whole-organism observation to one peptide alone (PMID 33916501).

How to read mechanism claims about GLP-2

Three distinctions keep the literature legible. First, receptor-level facts (one known receptor, class B GPCR, restricted expression) are better established than mediator-level claims, which rest heavily on animal and in-vitro work (PMID 16602931). Second, mucosal growth and absorptive adaptation have been described in both preclinical and clinical contexts, whereas lipid and bone effects remain framed as areas of active investigation (PMID 38426205). Third, pharmacokinetics matter to interpretation: the native peptide's rapid DPP-4 inactivation means findings from native GLP-2 and from DPP-4-resistant analogues are not interchangeable (PMID 11297614).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any decision involving a medicine or investigational compound. No dose, schedule or protocol is described here, and nothing above is an outcome claim.

References

• Proglucagon-derived peptides: human physiology and therapeutic potential (Physiological Reviews, 2026)
• Proglucagon-Derived Peptides as Therapeutics (Frontiers in Endocrinology, 2021)
• Glucagon-like Peptide-2 (Annual Review of Nutrition, 2006)
• Glucagon-like peptide 2 (The Journal of Clinical Endocrinology and Metabolism, 2001)
• Gastrointestinal defense mechanisms (Current Opinion in Gastroenterology, 2016)
• GLP-2 regulation of intestinal lipid handling (Frontiers in Physiology, 2024)
• Incretins and Lipid Metabolism (Current Medicinal Chemistry, 2018)
• Enterohormone therapy for short bowel syndrome (Current Opinion in Endocrinology, Diabetes, and Obesity, 2022)
• Treating short bowel syndrome with pharmacotherapy (Expert Opinion on Pharmacotherapy, 2020)
• The Gut-Bone Axis in Diabetes (Current Osteoporosis Reports, 2023)
• GLP-1 and Intestinal Diseases (Biomedicines, 2021)